+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 20 Actively Recruiting clinical trials

L

Actively Recruiting

Researchers are studying long-term treatment options for patients with advanced solid tumors, including non-small cell lung cancer and colorectal cancer, who previously participated in studies involving adagrasib either alone or with other cancer therapies. This open-label continuation trial enrolls patients from ongoing parent studies to evaluate the ongoing effects and safety of these treatments. The trial is sponsored by Mirati Therapeutics Inc. and aims to provide insights into long-term treatment outcomes for these cancer types. Participants receive adagrasib and may also receive other cancer drugs such as pembrolizumab, cetuximab, pemetrexed, docetaxel, irinotecan, leucovorin, oxaliplatin, or fluorouracil. These drugs are given at specified doses on specified days within the trial. The study includes multiple experimental arms, reflecting different treatment combinations or sequences based on prior parent study participation. During the study, participants are monitored for adverse events, including serious side effects and events leading to treatment discontinuation or death, for up to 90 days after their last dose or if they stop the study early. Researchers track safety and tolerability through regular assessments. Participants remain under observation for the duration of their involvement, which extends until the study completion date in February 2028.

Age: 18Years +All GendersPhase 2
101 locations
R

Actively Recruiting

Researchers are evaluating treatments for participants with metastatic colorectal cancer mCRC who have previously received irinotecan, oxaliplatin, a fluoropyrimidine, and bevacizumab. The study aims to compare overall survival when using precemtabart tocentecan Precem-TcT alone, Precem-TcT combined with bevacizumab, and trifluridinetipiracil FTD-TPI plus bevacizumab. This Phase 3 trial addresses the unmet need for effective treatment options in this patient group. Participants will be randomly assigned to one of three groups Precem-TcT alone given intravenously every 3 weeks on Day 1 of each 21-day cycle Precem-TcT combined with bevacizumab administered intravenously every 3 weeks or every 2 weeks depending on the cycle or FTD-TPI tablets taken orally twice daily on Days 1 to 5 and Days 8 to 12 of each 28-day cycle along with bevacizumab. The study evaluates these treatments over cycles lasting up to an average of 19 months. During the study, participants will undergo various assessments including survival monitoring, disease progression checks, response evaluations using RECIST criteria, adverse event tracking, and quality of life questionnaires. Blood samples will be collected at specific times to measure drug concentrations and immune response markers. Researchers will assess physical functioning and health status repeatedly until treatment ends, with safety and treatment effects monitored throughout the trial period.

Age: 18Years +All GendersPhase 3
92 locations
R

Actively Recruiting

Researchers are studying Raludotatug Deruxtecan R-DXd, an antibody-drug conjugate that targets CDH6 protein, in people with platinum-resistant, high-grade ovarian, primary peritoneal, or fallopian tube cancer. This trial includes a Phase 2 dose-optimization part to find the best dose based on safety and effectiveness, followed by a Phase 3 part comparing R-DXd to chemotherapy chosen by the investigator. Participants will receive R-DXd through an intravenous infusion every three weeks at varying doses during Phase 2. In Phase 3, participants will be randomly assigned to receive either R-DXd at the recommended dose or one of the chemotherapy options paclitaxel, pegylated liposomal doxorubicin PLD, or topotecan, also given intravenously every three weeks. During the study, participants will undergo scans and biopsies to evaluate tumor response and drug effects. Researchers will monitor safety, side effects, and various measures such as progression-free survival and overall survival for up to 40 months. Participants will have regular visits for treatment, assessments, and laboratory tests to track their health and response to the study treatments.

Age: 18Years +All GendersPhase 2Phase 3
167 locations
T

Actively Recruiting

Researchers are studying the use of Trastuzumab Deruxtecan T-DXd as an adjuvant treatment compared to standard chemotherapy, with or without radiotherapy, in women with newly diagnosed HER2-expressing endometrial cancer. This phase 3, open-label global trial aims to assess the safety and effectiveness of these treatments in participants who have not previously received anticancer therapy. The study focuses on participants with specific stages and various levels of HER2 expression in their cancer. Participants will be randomly assigned to receive either T-DXd at a dose of 5.4 mgkg intravenously every three weeks, with optional radiotherapy, or standard chemotherapy consisting of carboplatin and paclitaxel given every three weeks, with or without radiotherapy or chemoradiotherapy including cisplatin as a radiosensitizer. This comparison will evaluate how well these treatments work as adjuvant therapy following surgery. The study will continue until disease recurrence or other defined endpoints. During the study, participants will be monitored for disease-free survival using imaging reviewed by a blinded independent central review or local histopathologic confirmation, up to about 51 months after randomization. Overall survival will also be tracked up to approximately 63 months. Assessments will include radiographic evaluations and safety monitoring. Participants can expect regular visits for treatment and follow-up over several years to measure outcomes and ensure safety throughout the trial period.

Age: 18Years +FEMALEPhase 3
86 locations
R

Actively Recruiting

Researchers are evaluating the combination of TRK-950 with ramucirumab and paclitaxel compared to ramucirumab and paclitaxel alone in people with gastric or gastro-esophageal junction adenocarcinoma. The study aims to assess the effectiveness, safety, best dose, and development of anti-drug and neutralizing antibodies of TRK-950. This is a phase 2 randomized trial focused on progression-free survival as the main outcome, along with other measures like overall survival and response rates. Participants are assigned to one of three groups one receiving 5 mgkg TRK-950 plus ramucirumab and paclitaxel, another receiving 10 mgkg TRK-950 plus the same drugs, and a third group receiving ramucirumab and paclitaxel alone. Treatments are given intravenously following a 28-day cycle schedule, with specific dosing days for each drug. The study compares these groups to find the optimal dose and monitor drug interactions and immune responses. During the trial, participants will have regular assessments including scans, clinical evaluations, and laboratory tests to monitor disease progression and side effects. Researchers will track pharmacokinetics, antibody development, and quality of life using questionnaires throughout the study, which may last up to about 24 months. Safety monitoring will continue for 45 days after the last study dose, ensuring close follow-up for any adverse events or treatment effects.

Age: 18Years +All GendersPhase 2
27 locations
R

Actively Recruiting

Researchers are evaluating whether the drug PF-08046054 works better alone compared to the standard chemotherapy docetaxel in adults with non-small cell lung cancer NSCLC who have tumors expressing PD-L1 at 1% or higher. These participants have cancer that has spread in their body or cannot be removed by surgery or treated with radiation. All participants must have experienced disease progression during or after treatment with PD-L1 or PD-1 inhibitors, platinum-based chemotherapy, and targeted therapies if they have specific genetic mutations. Participants are randomly assigned to one of two groups. One group receives PF-08046054 through an intravenous IV infusion twice every 21-day cycle, while the other group receives docetaxel as an IV infusion once every 21 days. The study may last up to 5 years if the participants cancer responds to treatment. This phase 3 study compares the two therapies to understand their impact on survival and disease progression. During the study, participants will visit the clinic regularly to monitor their health and response to treatment. Researchers will measure overall survival and other outcomes such as progression-free survival, response rates, duration of response, and quality of life using questionnaires. Safety will also be monitored through adverse event evaluations. The study includes biomarker analysis using tumor tissue samples and tracks drug levels and immune responses over time.

Age: 18Years +All GendersPhase 3
447 locations
C

Actively Recruiting

Researchers are evaluating an experimental drug combination of fianlimab and cemiplimab compared to the approved combination of relatlimab and nivolumab in adults with unresectable or metastatic melanoma, a serious skin cancer. The study aims to assess the safety and effectiveness of these treatments, including side effects and how the body responds to the drugs. It is a phase 3 clinical trial designed to compare these regimens directly. Participants receive intravenous doses of either fianlimab plus cemiplimab every 3 weeks or relatlimab plus nivolumab every 4 weeks. The study randomly assigns patients to one of these two treatment groups. Treatment continues while monitoring for response and side effects, with the study lasting up to 72 months for assessing outcomes. During the trial, participants undergo regular evaluations including scans to measure tumor response, blood tests to monitor drug levels and antibodies against the drugs, and assessments of side effects. Researchers collect data on overall survival, disease control, and safety throughout the study period. Follow-up and monitoring may continue for several years to fully understand the treatments impacts.

Age: 18Years +All GendersPhase 3
113 locations
R

Actively Recruiting

Researchers are conducting a randomized controlled trial to compare survival outcomes between robotic-assisted laparoscopy and open hysterectomy with lymph node assessment for early-stage cervical cancer. The study aims to determine if robotic hysterectomy with tumor containment before colpotomy is not worse than abdominal hysterectomy in terms of disease-free survival. It includes patients with specific cervical cancer stages and tumor sizes suitable for surgery. Participants will undergo either a radical or simple hysterectomy using either traditional open surgery or a robotic-assisted technique. In the robotic group, the vagina is closed before colpotomy, and certain vaginal manipulators are not allowed. Both groups may have salpingectomy and oophorectomy with or without ovarian transposition. Surgeons will document operative details, including any complications, blood loss, and reasons for conversion to open surgery. During the trial, participants will be closely monitored with preoperative assessments like labs, EKG, and MRI to confirm eligibility. Surgical findings and complications will be recorded. The primary outcome measured is survival at 36 months. Participants must provide informed consent and undergo follow-up to assess disease status and survival over the study period, which extends until 2030.

Age: 18Years +FEMALEPhase Not Applicable
156 locations
E

Actively Recruiting

Healthy Volunteer

Researchers are investigating the safety and effectiveness of Fertilo compared to Medicult IVM for in vitro maturation IVM of eggs in women aged 18 to 35. The study aims to find out if Fertilo leads to better pregnancy outcomes, specifically looking at the number of ongoing pregnancies at 12 weeks gestation. This phase III randomized trial compares these two methods to improve infertility treatment. Participants will be randomly assigned to one of two groups. In the first group, immature eggs surrounded by supportive cells are cultured in Fertilo for 30 hours. In the second group, the eggs are cultured in the standard Medicult IVM system for the same duration. After maturation, eggs in both groups are fertilized, grown to the blastocyst stage, frozen, and later transferred for reproductive purposes. During the study, participants will undergo assessments including hormone level measurements, ultrasounds, and sperm analysis for male partners. Researchers will track several outcomes such as egg maturation rate, fertilization success, embryo development, pregnancy rates, and live births. The trial includes safety monitoring and follow-up until at least 12 weeks of pregnancy, with the total study period expected to last until early 2028.

Age: 18Years - 35YearsFEMALEPhase 3
16 locations
O

Actively Recruiting

This research aims to evaluate patient outcomes following shoulder replacement surgery using FX Shoulder Solutions medical devices. The study observes patients who have received these legally marketed devices in the USA to assess their safety, effectiveness, and long-term survivorship. The registry collects data to support regulatory requirements and share findings through presentations and publications. Participants are those implanted with FX Shoulder Solutions shoulder replacement devices, including various systems like Humelock II and Easytech Anatomical Shoulder System. The registry tracks these patients from surgery onward, with key follow-ups at 2 years to assess clinical success and up to 10 years to monitor device survivorship. Success is defined by measures such as improved shoulder function, no device migration, no revision surgery, and absence of serious device-related adverse events. During the study, patients undergo evaluations at multiple time points including 6 weeks, 3, 6, 12, and 24 months post-surgery using standardized scores like Adjusted Constant Score, QuickDASH, and Visual Analog Scale. Radiographic reviews, range of motion assessments, and tracking of adverse events and secondary surgeries occur up to 5 years. The study involves ongoing monitoring to understand the long-term performance and safety of the shoulder replacement devices.

All AgesAll Genders
4 locations

1-10 of 20

1